(Total Views: 556)
Posted On: 08/19/2025 5:09:25 PM
Post# of 156150
Feb. 6th, 2025:
As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”
March 18th:
Instead, we are continuing discussions with potential partners who have expressed interest in funding studies of leronlimab in the treatment of patients with organ fibrosis to build on the promising findings listed above.
__
Could be our break-out on progressing multiple observations @ once....
Announcing "multiple organs" is finalized, will be phenomenal for LL.
: )))
As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”
March 18th:
Instead, we are continuing discussions with potential partners who have expressed interest in funding studies of leronlimab in the treatment of patients with organ fibrosis to build on the promising findings listed above.
__
Could be our break-out on progressing multiple observations @ once....
Announcing "multiple organs" is finalized, will be phenomenal for LL.
: )))
(18)
(0)
